Detection of insulin-like growth factor-2 variants by mass spectrometry
Through high-resolution mass spectrometry and HPLC purification technology, insulin-like growth factor 2 (IGF-2) variants were detected and quantified, and the problem of polymorphic variants being "hidden" in the prior art was solved, achieving the IGF- Accurate detection and quantification of 2 variants.
Patent Information
- Application Number
- CN202380032805.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-07
- Filing Date
- 2023-04-07
- Publication Date
- 2024-11-22
AI Technical Summary
Existing mass spectrometry is difficult to detect and quantify insulin-like growth factor 2 (IGF-2) variants, especially the mass changes caused by amino acid substitution caused by polymorphism, which makes the polymorphic variant "hidden", while existing Methods were able to quantify only wild-type IGF-2 without polymorphic variants.
Detection of IGF-2 variants in samples by high resolution mass spectrometry, which includes ionizing the sample and detecting ions with a specific mass-to-charge ratio by mass spectrometry, such as ions of 1089.8±0.5 or 1090.23, combined with high performance liquid chromatography The presence of IGF-2 variants was determined by using HPLC purification and mass spectrometry.
Effective detection and quantification of IGF-2 variants are achieved, variants with additional arginine can be identified and quantified, the detection ability of polymorphic variants is improved, and the accuracy and accuracy of quantification are ensured.
Smart Images

Figure CN119013561A_ABST
Abstract
Description
[0001] Cross-references to related patent applications
[0002] This application claims priority to U.S. Provisional Application No. 63 / 328,649, filed on April 7, 2022, the contents of which are incorporated by reference in their entirety. Technical Field
[0003] The present invention relates to the identification and quantification of insulin-like growth factor 2 variants using mass spectrometry. Background Art
[0004] Insulin-like growth factor 2 (IGF-II or IGF-2) plays a vital role in growth and development before birth. Research shows that IGF-2 promotes the growth and division of cells in many different tissues. Although the IGF-2 gene is highly active during fetal development, its activity is greatly reduced after birth.
[0005] High-resolution LC-MS-based methods are effective for quantifying peptides in samples from most patients, but amino acid substitutions due to polymorphisms can result in mass changes that essentially "hide" the polymorphic variant. When monitoring larger peptides with more amino acid residues, the likelihood of having a polymorphism increases.
[0006] Since protein quantification is based on the peak intensity of a specific mass-to-charge ratio (m / z) of the wild-type (WT) protein, IGF-2 quantification only includes the WT but not the polymorphism.Described herein is a method for detecting novel IGF-2 variants. Summary of the invention
[0007] The methods provided herein include detecting and quantifying one or more novel IGF-2 variants by mass spectrometry.
[0008] In some embodiments, the method comprises detecting the following mass / charge (m / z) ratio for each of the variants of interest:
[0009] In some embodiments, the method provided herein is a method for detecting insulin-like growth factor-2 (IGF-2) variants in a sample, the method comprising: ionizing IGF-2 in the sample to produce one or more ions that can be detected by mass spectrometry; detecting one or more of the ions by mass spectrometry, the one or more ions including ions with a mass-to-charge ratio of 1089.8±0.5; and using the detected one or more ions to determine the presence of the IGF2 variant in the sample.
[0010] In some embodiments, the method includes detecting one or more of the ions by mass spectrometry, the one or more ions including ions having a mass-to-charge ratio of 1089.66±0.5.
[0011] In some embodiments, the method includes detecting one or more of the ions by mass spectrometry, the one or more ions including ions having a mass-to-charge ratio of 1090.23±0.5.
[0012] In some embodiments, the methods provided herein detect variants having an additional arginine at position 68.
[0013] In some embodiments, the methods provided herein comprise purifying the protein by high performance liquid chromatography (HPLC) prior to ionization.
[0014] In some embodiments, the sample comprises plasma or serum.
[0015] In some embodiments, the sample may be purified by high performance liquid chromatography (HPLC) prior to ionization. In a related embodiment, IGF-2 and its variants are extracted and separated using a multiplex high performance liquid chromatography (HPLC) system (Aria TLX-4) equipped with online extraction.
[0016] In some embodiments, the sample can be purified by solid phase extraction (SPE) prior to ionization.
[0017] In some embodiments, the mass spectrometry comprises a Q Exactive Focus hybrid quadrupole-orbitrap instrument.
[0018] In some embodiments, high resolution / high accuracy mass spectrometry is performed with a resolving power (FWHM) greater than or equal to about 10,000, such as greater than or equal to about 15,000, such as greater than or equal to about 20,000, such as greater than or equal to about 25,000. In some embodiments, high resolution / high accuracy mass spectrometry is performed with an accuracy of less than or equal to about 50 ppm, such as less than or equal to about 20 ppm, such as less than or equal to about 10 ppm, such as less than or equal to about 5 ppm; such as less than or equal to about 3 ppm. In some embodiments, high resolution / high accuracy mass spectrometry is performed with a resolving power (FWHM) greater than or equal to about 10,000 and an accuracy of less than or equal to about 50 ppm. In some embodiments, the resolving power is greater than about 15,000 and the accuracy is less than or equal to about 20 ppm. In some embodiments, the resolution is greater than or equal to about 20,000 and the accuracy is less than or equal to about 10 ppm, preferably the resolution is greater than or equal to about 25,000 and the accuracy is less than or equal to about 5 ppm, such as less than or equal to about 3 ppm.
[0019] In some embodiments, high resolution / high accuracy mass spectrometry may be performed using an orbitrap mass spectrometer, a time of flight (TOF) mass spectrometer, or a Fourier transform ion cyclotron resonance mass spectrometer (sometimes referred to as a Fourier transform mass spectrometer). In some embodiments, the sample may comprise a biological sample; preferably plasma or serum.
[0020] In some embodiments, correlating the amount of one or more IGF-2 ions detected by mass spectrometry with the amount of IGF-2 protein in the sample comprises comparing with an internal standard, such as a human or non-human IGF-2 protein (e.g., recombinant mouse recombinant mouse IGF-2). The internal standard may optionally be isotopically labeled.
[0021] The features of the embodiments listed above can be used in combination in the method of the present invention without restriction.
[0022] In certain preferred embodiments, mass spectrometry is carried out in positive ion mode. Alternatively, mass spectrometry is carried out in negative ion mode. The preferred ionization technique used in the method described herein is electrospray ionization (ESI). For example, electrospray ionization can be carried out with a heated ionization source. In certain embodiments, the method provided herein includes heated electrospray ionization (HESI). In certain embodiments, the method provided herein includes heated electrospray ionization (HESI) in positive ion mode.
[0023] In preferred embodiments, one or more separately detectable internal standards are provided in the sample, and the amount of the internal standards is also determined in the sample. In these embodiments, all or a portion of both the analyte of interest and the one or more internal standards are ionized to produce a plurality of ions detectable in a mass spectrometer, and the one or more ions produced by each of the analyte of interest and the one or more internal standards are detected by mass spectrometry. The internal standard can be selected from the group consisting of non-human IGF-2 (e.g., isotope-labeled or unlabeled recombinant mouse IGF-2), isotope-labeled human IGF-2 protein.
[0024] In other embodiments, the amount of IGF-2 variant protein in a sample can be determined by comparison with one or more external reference standards. Exemplary external reference standards include blank plasma or serum spiked with isotopically labeled or unlabeled human or non-human IGF-2 (e.g., isotopically labeled or unlabeled recombinant mouse IGF-2).
[0025] In some embodiments, the isotopic signature of the mass spectrum peaks including two or more molecular isotopic forms from the analyte can be used to confirm the identity of the analyte under study. In other embodiments, the mass spectrum peaks from one or more isotopic forms can be used for quantitatively paying attention to the analyte. In some related embodiments, a single mass spectrum peak from a kind of isotopic form can be used for quantitatively paying attention to the analyte. In other related embodiments, multiple isotopic peaks can be used for quantitative analysis. Multiple peaks can be subjected to any appropriate mathematical treatment. Several mathematical treatments are known in the art and include but are not limited to summing the areas under multiple peaks, or averaging the responses from multiple peaks.
[0026] As used herein, the singular forms "a", "an", and "the" include plural references unless otherwise indicated. Thus, for example, reference to "a protein" includes a plurality of protein molecules.
[0027] As used herein, the term "IGF-2 protein" refers to a full-length IGF-2 polypeptide or a fragment thereof, and a full-length IGF-2 variant polypeptide or a fragment thereof. Exemplary chemical modifications may include reduction of one or more disulfide bonds or alkylation of one or more cystines. These exemplary chemical modifications increase the mass of the IGF-2 variant polypeptide relative to the mass of the corresponding unmodified IGF-2 polypeptide. Reduction of one or more disulfide bonds results in a relatively small change in the mass of the molecule, wherein the resulting mass-to-charge ratio falls within the range of mass-to-charge ratios described herein. Other chemical modifications that result in a deviation from the mass of the unmodified IGF-2 polypeptide are also encompassed within the meaning of the IGF-2 protein. It is understood by those skilled in the art that the addition of atoms to the IGF-2 protein by chemical modification will increase the mass-to-charge ratio observed during mass spectrometry. Therefore, the IGF-2 protein variants produced by chemical modification are included within the meaning of the IGF-2 protein and can be detected according to the methods of the present invention.
[0028] As used herein, the term "intact" as used to describe a polypeptide refers to a full-length (i.e., non-fragmented) polypeptide. Non-intact forms (i.e., fragments) of IGF-2 can also be detected by the methods described herein. For example, fragments of IGF-2 proteins having a molecular weight of about 1,000 Daltons or greater, such as about 1500 Daltons or greater, such as about 2000 Daltons or greater, such as about 2500 Daltons or greater, such as about 3000 Daltons or greater, such as about 4000 Daltons or greater, such as about 5000 Daltons or greater, such as about 6000 Daltons or greater, such as about 7000 Daltons or greater can be detected by the methods described herein.
[0029] The term "purification" or "purifying" refers to the procedure of enriching the amount of one or more analytes of interest relative to other components in the sample that may interfere with the detection of the analyte of interest. Although not required, "purification" can completely remove all interfering components, or even all materials except the analyte of interest. Purifying a sample by various methods can allow for a relative reduction in one or more interfering substances, for example, one or more substances that may or may not interfere with the detection of a selected parent ion or daughter ion by mass spectrometry. When the term relative reduction is used, the relative reduction does not require that any substance present with the analyte of interest in the material to be purified is completely removed by purification.
[0030] The term "sample" refers to any sample that may contain an analyte of interest. As used herein, the term "body fluid" means any fluid that can be isolated from an individual's body. For example, a "body fluid" may include blood, plasma, serum, bile, saliva, urine, tears, sweat, etc. In a preferred embodiment, the sample comprises a body fluid sample; preferably plasma or serum.
[0031] The term "solid phase extraction" or "SPE" refers to a process in which a chemical mixture is separated into components due to the affinity of the components dissolved or suspended in the solution (i.e., mobile phase) to the solid (i.e., solid phase) through which the solution passes or bypasses. In some cases, as the mobile phase passes through or around the solid phase, undesirable components of the mobile phase may be retained by the solid phase, resulting in purification of the analyte in the mobile phase. In other cases, the analyte may be retained by the solid phase, thereby allowing undesirable components of the mobile phase to pass through or around the solid phase. In these cases, the retained analyte is then eluted from the solid phase using a second mobile phase for further processing or analysis. SPE can be operated by a single or mixed mode mechanism. As used herein, SPE can be performed with an extraction column or cartridge (e.g., a turbulent flow liquid chromatography (TFLC) column. The mixed mode mechanism utilizes ion exchange and hydrophobic retention in the same column; for example, the solid phase of a mixed mode SPE column may exhibit strong anion exchange and hydrophobic retention; or may exhibit strong cation exchange and hydrophobic retention.
[0032] The term "chromatography" refers to a process in which a chemical mixture carried by a liquid or gas is separated into components due to the differential distribution of the chemical entities when it passes over a stationary solid phase.
[0033] The term "liquid chromatography" or "LC" means the process of selectively delaying one or more components of a fluid solution as the fluid uniformly permeates through a column of finely divided material or through a capillary channel. The delay is caused by the distribution of components of the mixture between the one or more stationary phases and the bulk fluid (i.e., mobile phase) as the fluid moves relative to the stationary phase. Examples of separation techniques using "liquid chromatography" include reverse phase liquid chromatography (RPLC), high performance liquid chromatography (HPLC), and turbulent flow liquid chromatography (TFLC) (sometimes referred to as high turbulence liquid chromatography (HTLC) or high throughput liquid chromatography). In some embodiments, an SPE column can be used in combination with an LC column. For example, a sample can be purified with a TFLC extraction column and then additionally purified with an HPLC analytical column.
[0034] The term "high performance liquid chromatography" or "HPLC" (sometimes called "high pressure liquid chromatography") refers to liquid chromatography in which the degree of separation is increased by forcing the mobile phase under pressure through a stationary phase, usually through a densely packed column.
[0035] The term "turbulent flow liquid chromatography" or "TFLC" (sometimes referred to as high turbulence liquid chromatography or high throughput liquid chromatography) refers to a form of chromatography that uses the turbulence of the material being measured as it passes through the column packing as the basis for separation. TFLC has been applied to the preparation of samples containing two unnamed drugs prior to analysis by mass spectrometry. See, e.g., Zimmer et al., J Chromatogr A 854:23-35 (1999); see, e.g., U.S. Pat. Nos. 5,968,367, 5,919,368, 5,795,469, and 5,772,874, which further explain TFLC. "Turbulent flow" is understood by one of ordinary skill in the art. When a fluid flows slowly and smoothly, the flow is referred to as "laminar flow." For example, a fluid moving through an HPLC column at a low flow rate is laminar flow. In laminar flow, the motion of the fluid particles is orderly, with the particles generally moving in straight lines. At faster speeds, the inertia of the water overcomes fluid friction, creating turbulence. Fluid that is not in contact with irregular boundaries "outruns" fluid that is slowed by friction or deflected by uneven surfaces. When a fluid is flowing turbulently, it is flowing in eddies and vortices (or vortices) where the "drag" is greater than when the flow is laminar. Many references are available to help determine when a fluid flow is laminar or turbulent (e.g., Turbulence Analysis: Measurement and Prediction Flow Analysis: Measurement and Prediction)》 ,PSBernard andJM Allace, John Wiley & Sons, Inc., (2000); An Introduction to Turbulent Flow, Jean Mathieu and Julian Scott, Cambridge University Press (2001).
[0036] The term "gas chromatography" or "GC" refers to a chromatography method in which a sample mixture is vaporized and injected into a stream of carrier gas (such as nitrogen or helium) moving through a column containing a stationary phase composed of a liquid or particulate solid, and separated into its component compounds according to their affinity for the stationary phase.
[0037] For example, the terms "on-line" and "inline" as used in "on-line automated mode" or "on-line extraction" refer to procedures that are performed without the need for operator intervention. In contrast, the term "off-line" as used herein refers to procedures that require manual intervention by an operator. Thus, if a sample is subjected to precipitation, and the supernatant is then manually loaded into an autosampler, the precipitation and loading steps are offline from subsequent steps. In various embodiments of the method, one or more steps may be performed in an online automated mode.
[0038] The term "mass spectrometry" or "MS" refers to an analytical technique that identifies compounds by their masses. MS refers to a method of filtering, detecting, and measuring ions based on their mass-to-charge ratio, or "m / z." MS techniques generally involve (1) ionizing compounds to form charged compounds; and (2) detecting the molecular weight of the charged compounds and calculating the mass-to-charge ratio. Compounds may be ionized and detected by any suitable method. A "mass spectrometer" generally comprises an ionizer and an ion detector. Typically, one or more molecules of interest are ionized and the ions are then introduced into a mass spectrometer where, due to a combination of magnetic and electric fields, the ions follow a path in space that depends on mass ("m") and charge ("z"). See, e.g., U.S. Pat. Nos. 6,204,500, entitled “Mass Spectrometry From Surfaces”; 6,107,623, entitled “Methods and Apparatus for Tandem Mass Spectrometry”; 6,268,144, entitled “DNA Diagnostics Based On Mass Spectrometry”; 6,124,137, entitled “Surface-Enhanced Photolabile Attachment And Release For Desorption And Detection Of Analytes”; Wright et al., Prostate Cancer and Prostatic Diseases. Diseases, 1999, 2:264-76; and Merchant and Weinberger, Electrophoresis, 2000, 21:1164-67.
[0039] As used herein, "high resolution / high accuracy mass spectrometry" refers to mass spectrometry performed with a mass analyzer that is capable of measuring the mass-to-charge ratio of charged species with sufficient precision and accuracy to identify unique chemical ions. Identification of a unique chemical ion of an ion is possible when individual isotopic peaks from the ion are readily distinguishable. The specific resolving power and mass accuracy required to identify a unique chemical ion varies depending on the mass and charge state of the ion.
[0040] As used herein, the term "resolution" or "resolution (FWHM)" (also referred to in the art as "m / Δm 50% ”) refers to the observed mass-to-charge ratio divided by the width of the mass peak at 50% of its maximum height (full width at half maximum, “FWHM”). At this highest resolving power, individual isotopic peaks contain contributions below 1% of the baseline.
[0041] As used herein, a "unique chemical ion" with respect to mass spectrometry refers to a single ion having a single atomic composition. A single ion may be singly or multiply charged.
[0042] As used herein, the term "accuracy" (or "mass accuracy") with respect to mass spectrometry refers to the potential deviation of the instrument response from the true m / z of the ion being investigated. Accuracy is typically expressed in parts per million (ppm).
[0043] The high resolution / high accuracy mass spectrometry method of the present invention can be carried out on an instrument capable of mass analysis with a FWHM greater than 10,000, 15,000, 20,000, 25,000, 50,000, 100,000 or even higher. Similarly, the method of the present invention can be carried out on an instrument capable of mass analysis with an accuracy less than 50ppm, 20ppm, 15ppm, 10ppm, 5ppm, 3ppm or even lower. Instruments with these performance characteristics may include certain orbital trap mass analyzers, time of flight ("TOF") mass analyzers or Fourier transform ion cyclotron resonance mass analyzers. In a preferred embodiment, the method is carried out with an instrument comprising an orbital trap mass analyzer or a TOF mass analyzer.
[0044] The term "orbital trap" describes an ion trap consisting of an outer barrel electrode and a coaxial inner electrode. Ions are injected tangentially into the electric field between the electrodes and are trapped because the electrostatic interaction between the ions and the electrodes is balanced by the centrifugal force when the ions orbit the coaxial inner electrode. When the ions orbit the coaxial inner electrode, the orbital path of the trapped ions oscillates along the axis of the central electrode at a harmonic frequency relative to the mass-to-charge ratio of the ions. Detection of the orbital oscillation frequency allows the orbital trap to be used as a mass analyzer with high accuracy (as low as 1-2ppm) and high resolution (FWHM) (up to about 200,000). Mass analyzers based on orbital traps are described in detail in U.S. Patent No. 6,995,364, which is incorporated herein by reference in its entirety. It is reported that orbital trap analyzers are used for qualitative and quantitative analysis of various analytes. See, for example, U.S. Patent Application Publication No. 2008 / 0118932 (filed on November 9, 2007); et al., Rapid Commun. Mass Spectrom., 2008, 22:477-485; Le Breton et al., Rapid Commun. Mass Spectrom., 2008, 22:3130-36; Thevis et al., Mass Spectrom. Reviews, 2008, 27:35-50; Thomas et al., J. Mass Spectrom., 2008, 43:908-15; Schenk et al., BMC Medical Genomics, 2008, 1:41; and Olsen et al., Nature Methods, 2007, 4:709-12.
[0045] The term "operating in negative ion mode" refers to those mass spectrometry methods that generate and detect negative ions. As used herein, the term "operating in positive ion mode" refers to those mass spectrometry methods that generate and detect positive ions.
[0046] As used herein, the term "ionization" or "ionizing" refers to the process of producing ions having a net charge equal to one or more electron units. Negative ions are ions having a net negative charge of one or more electron units, while positive ions are ions having a net positive charge of one or more electron units.
[0047] The term "selective ion monitoring" is a detection mode of a mass spectrometer in which only ions within a relatively narrow mass range (usually about one mass unit or less) are detected.
[0048] "Multiple reaction mode", sometimes referred to as "selected reaction monitoring", is a detection mode for a mass spectrometer in which a precursor ion and one or more fragment ions are selectively detected.
[0049] The term "lower limit of quantification", "lower limit of quantitation" or "LLOQ" refers to the point at which a measurement becomes quantitatively meaningful. The analyte response at this LLOQ is identifiable, discrete and reproducible with a relative standard deviation (RSD%) of less than 20% and an accuracy of 85% to 115%.
[0050] The term "limit of detection" or "LOD" refers to the point at which a measurement is greater than the uncertainty associated with its measurement. The LOD is defined as four times the RSD of the mean at zero concentration.
[0051] The term "simultaneous" as applied to the simultaneous detection of the amount of two or more analytes from a sample means obtaining data reflecting the amount of two or more analytes in the sample from the same sample injection. Depending on the instrument technology used, the data of each analyte can be acquired sequentially or in parallel. For example, a single sample containing two analytes (such as IGF-1 and IGF-2 proteins) can be injected into an HPLC column, and then each analyte is eluted in sequence, thereby introducing the analytes sequentially into a mass spectrometer. Since these two analytes are produced by the injection of the same sample into HPLC, for the purpose of this article, the amount of each analyte in these two analytes is determined simultaneously.
[0052] The "amount" of an analyte in a bodily fluid sample generally refers to an absolute value reflecting the mass of the analyte detectable in the sample volume. However, the amount also encompasses a relative amount compared to another amount of an analyte. For example, the amount of an analyte in a sample can be an amount greater than a control or normal level of the analyte normally present in the sample.
[0053] As used herein, the term "about" refers to a quantitative measurement that does not include the mass measurement of the ion and refers to the indicated value ± 10%. Mass spectrometry instruments vary slightly in determining the mass of a given analyte. The term "about" in the context of ion mass or ion mass-to-charge ratio refers to + / - 0.50 atomic mass units.
[0054] The above description of the summary of the invention is non-limiting and other features and advantages of the invention will be apparent from the following detailed description of the invention and the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] Figure 1 Shown is the mass spectrometric detection of a previously unknown variant of IGF-2 (IGF-2+68R).
[0056] Figure 2 Mass spectrometric differences between an unknown variant of IGF-2 and IGF-1 wild type (WT) are shown.
[0057] Figure 3 An improved mass spectrum of an unknown variant of IGF-2 (IGF-2+68R) is shown.
[0058] Figure 4 Basic Local Alignment Search Tool (BLAST) search results for an unknown variant of IGF-2 (IGF-2+68R) are shown.
[0059] Figure 5 Shown is the mass spectrum of a novel variant of IGF-2 (IGF-2+68R).
[0060] Figure 6 A schematic diagram of the IGF-2 protein domains is shown. DETAILED DESCRIPTION
[0061] Suitable test samples for the methods of the present invention include any test sample that may contain the analyte of interest. In some preferred embodiments, the sample is a biological sample; that is, a sample obtained from any biological source, such as an animal, a cell culture, an organ culture, etc. In certain preferred embodiments, the sample is obtained from a mammal (such as a dog, a cat, a horse, etc.). Particularly preferred mammals are primates, most preferably male or female humans. Preferred samples include body fluids such as blood, plasma, serum, saliva, cerebrospinal fluid, or tissue samples; preferably plasma and serum. Such samples can be obtained, for example, from a patient (i.e., a living person, whether male or female, who appears in a clinical setting for diagnosis, prognosis, or treatment of a disease or condition).
[0062] Quality control (QC) pools of known concentration used in embodiments of the present invention are preferably prepared using a matrix similar to the intended sample matrix.
[0063] Sample preparation for mass spectrometry analysis
[0064] In preparation for mass spectrometry analysis, IGF-2 protein can be enriched relative to one or more other components (e.g., other proteins) in a sample by various methods known in the art, including, for example, solid phase extraction (SPE), LC, filtration, centrifugation, thin layer chromatography (TLC), electrophoresis including capillary electrophoresis, affinity separation including immunoaffinity separation, extraction methods including ethyl acetate or methanol extraction, and use of chaotropic agents or any combination of the above methods, etc. In some embodiments, liquid chromatography and / or SPE and / or protein precipitation can be used in combination.
[0065] Protein precipitation is a method for preparing a test sample, especially a biological sample (such as serum or plasma). Protein purification methods are well known in the art, for example, Polson et al., Journal of Chromatography B 2003, 785: 263-275, describes a protein precipitation technique suitable for the method of the present invention. Protein precipitation can be used to remove most of the protein from the sample, leaving IGF-I and / or IGF-II protein in the supernatant. The sample can be centrifuged to separate the liquid supernatant from the precipitated protein; alternatively, the sample can be filtered to remove the precipitated protein. The resulting supernatant or filtrate can then be directly applied to mass spectrometry analysis; or alternatively used for solid phase extraction and / or liquid chromatography and subsequent mass spectrometry analysis. In certain embodiments, the use of protein precipitation (e.g., acidic ethanol protein precipitation) can avoid the need for TFLC, SPE or other online extraction before mass spectrometry or HPLC and mass spectrometry.
[0066] In a preferred embodiment, a liquid-liquid extraction method (such as acidic ethanol extraction) is used to extract natural IGF-2 variants from a sample. In these embodiments, a sample between 10 μl and 500 μl (such as between 25 μl and 250 μl, such as about 100 μl) is added to a portion of an extraction solvent. The amount of the extraction solvent is comparable to the sample volume and can vary depending on the extraction solvent used, but is preferably between about 50 μl and 1000 μl. The sample / solvent mixture is mixed and centrifuged, and a portion of the supernatant or organic phase (depending on the solvent used) is extracted for further analysis. The solvent can be removed from the extracted portion, for example, under a nitrogen stream, and the residue can be reconstructed in a solvent different from the solvent used for liquid-liquid extraction. Then, before mass spectrometry, at least a portion of the resulting solution can be subjected to additional processing steps, such as SPE and / or LC.
[0067] Another method of sample purification that can be used before mass spectrometry is liquid chromatography (LC). Some methods of liquid chromatography include HPLC, which relies on relatively slow laminar flow technology. Traditional HPLC analysis relies on column packing, in which the laminar flow of the sample through the column is the basis for separating the analyte of interest from the sample. It will be appreciated by those skilled in the art that separation in such columns is a diffusion process, and LC (including HPLC, instrument and column) suitable for use with IGF-2 can be selected. Chromatographic columns generally include a medium (i.e., a packing material) for promoting the separation (i.e., classification) of chemical moieties. The medium may include tiny particles, or may include a monolithic material with porous channels. The surface of the medium generally includes a bonding surface that interacts with various chemical moieties to promote the separation of chemical moieties. A suitable bonding surface is a hydrophobic bonding surface, such as an alkyl bonding or a cyano bonding surface. The alkyl bonding surface may include an alkyl bonded by C-4, C-8, C-12 or C-18. In a preferred embodiment, the column is a C-18 alkyl bonded column (such as a Phenomenex Onyx monolithic C-18 column). The chromatographic column comprises an inlet port for receiving a sample and an outlet port for discharging an effluent comprising the fractionated sample. The sample can be applied directly to the inlet port, or from an SPE column, such as an online SPE guard cartridge or a TFLC column.
[0068] In one embodiment, the sample can be applied to the LC column at the inlet port, eluted with a solvent or solvent mixture, and discharged at the outlet port. Different solvent modes can be selected to elute the analyte of interest. For example, liquid chromatography can be performed using a gradient mode, an isocratic mode, or a polymorphic (i.e., mixed) mode. During chromatography, the separation of materials is affected by a variety of factors, such as eluent (also referred to as "mobile phase"), elution mode, gradient conditions, temperature, etc.
[0069] In certain embodiments, the analyte can be purified by applying a sample to a column under the condition that the analyte of interest is reversibly retained by the column packing material, while one or more other materials are not retained. In these embodiments, a first mobile phase condition can be adopted under the condition that the analyte of interest is retained by the column, and a second mobile phase condition can be subsequently adopted to remove the retained material from the column after the unretained material is washed through. Alternatively, the analyte can be purified by applying a sample to a column under the mobile phase condition that the analyte of interest is eluted at a different rate than one or more other materials. Such a procedure can enrich the amount of one or more analytes of interest relative to one or more other components of the sample.
[0070] In some embodiments, HPLC is performed using an alkyl bonded analytical column chromatography system. In certain embodiments, a C-18 analytical column (e.g., Phenomenex Onyx monolithic C18 or equivalent) is used. In certain embodiments, HPLC and / or TFLC is performed using HPLC grade 0.2% formic acid / water as mobile phase A and 0.2% formic acid / acetonitrile as mobile phase B.
[0071] By carefully selecting valves and connector tubing, two or more chromatography columns can be connected as needed so that material is transferred from one chromatography column to the next without any manual steps. In a preferred embodiment, the selection of valves and tubing is controlled by a preprogrammed computer to perform the necessary steps. Most preferably, the chromatography system is also connected to a detector system, such as an MS system, in such an online manner. Thus, an operator can place a tray of samples in an autosampler and have the remaining operations performed under computer control so that all selected samples are purified and analyzed.
[0072] In some embodiments, TFLC can be used to purify IGF-2 protein or fragments prior to mass spectrometry. In such embodiments, the sample can be extracted using a TFLC column that captures the analyte and then eluted on a second TFLC column or on an analytical HPLC column and analyzed by chromatography prior to ionization. For example, sample extraction using a TFLC extraction column can be accomplished using a large particle size (50 μm) packed column. The sample eluted from this column can then be transferred to an HPLC analytical column for further purification prior to mass spectrometry. Because the steps involved in these chromatography procedures can be connected in an automated manner, the requirement for operator involvement can be minimized during the purification of the analyte. This feature can save time and cost and eliminate the opportunity for operator error.
[0073] In some embodiments, protein precipitation is achieved by acidic ethanol extraction from serum and the resulting solution is subjected to SPE, preferably performed online with a C-18 extraction column (e.g., Phenomenex Onyx C-18 guard cartridge or equivalent). The eluate from the SPE column can then be applied to an analytical LC column (e.g., HPLC column) in an online manner prior to mass spectrometry analysis.
[0074] Detection and quantification by mass spectrometry
[0075] Mass spectrometry is performed using a mass spectrometer comprising an ion source for ionizing the sample and generating charged molecules for further analysis. In various embodiments, the IGF-2 protein can be ionized by any suitable method known to those skilled in the art. For example, the sample can be ionized by the following methods: electron ionization, chemical ionization, electrospray ionization (ESI), photon ionization, atmospheric pressure chemical ionization (APCI), photoionization, atmospheric pressure photoionization (APPI), fast atom bombardment (FAB), liquid secondary ionization (LSI), matrix-assisted laser desorption ionization (MALDI), field ionization, field desorption, thermal spray / plasma spray ionization, surface enhanced laser desorption ionization (SELDI), inductively coupled plasma (ICP), particle beam ionization. It will be appreciated by those skilled in the art that the selection of ionization methods can be determined based on the analyte to be measured, the type of sample, the type of detector, the selection of positive mode to negative mode, etc. Depending on the specific ionization method and conditions used, the IGF-2 protein can be ionized into a variety of different charge states. The ionization source can be selected to minimize the dispersion of the generated charge state. In some embodiments, ESI (optionally heated) is used as the ionization source, and the ionization conditions are optimized to minimize the diffusion of the observed multiply charged IGF-2 protein ions.
[0076] The IGF-2 protein can be ionized in positive mode or negative mode. In a preferred embodiment, one or more IGF-2 proteins are ionized in positive mode. Most of the multiply charged ions generated within these ranges may fall into a narrower sub-range, such as within the indicated m / z ± 1.
[0077] Typically, in mass spectrometry techniques, after the sample has been ionized, the resulting positively or negatively charged ions can be analyzed to determine the mass-to-charge ratio (m / z). Various analyzers for determining m / z include quadrupole analyzers, ion trap analyzers, time-of-flight analyzers, and orbital trap analyzers. According to the method of the present invention, high-resolution / high-accuracy mass spectrometry is used for quantitative analysis of IGF-2 protein. That is, mass spectrometry is performed with a mass spectrometer capable of exhibiting a resolving power (FWHM) of at least 10,000, with an accuracy of about 50ppm or less for the ions of interest; preferably, the mass spectrometer exhibits a resolving power (FWHM) of 20,000 or better and an accuracy of about 20ppm or less; such as a resolving power (FWHM) of 25,000 or better and an accuracy of about 5ppm or less; such as a resolving power (FWHM) of 25,000 or better and an accuracy of about 3ppm or less. Three exemplary mass spectrometers that can demonstrate the desired performance levels for IGF-2 protein ions are mass spectrometers comprising orbitrap mass analyzers, certain TOF mass analyzers, or Fourier transform ion cyclotron resonance mass analyzers.
[0078] Elements found in biologically active molecules, such as carbon, oxygen, and nitrogen, naturally exist in a variety of different isotopic forms. For example, most carbon exists as 12 C exists, but about 1% of all naturally occurring carbon is found as 13 C exists. Therefore, a fraction of naturally occurring carbon-containing molecules will contain at least one 13 C atoms. Molecules containing naturally occurring isotopes of elements will produce a variety of molecular isotopic forms. The mass difference of molecular isotopic forms is at least 1 atomic mass unit (amu). This is because the element isotopes differ by at least one neutron (the mass of a neutron ≈ 1amu). When the molecular isotopic forms are ionized into multiple charge states, the mass difference between the isotopic forms may become difficult to distinguish because mass spectrometry is based on the mass-to-charge ratio (m / z). For example, the m / z difference of two isotopic forms that are both ionized into 5+ states with a mass difference of 1amu is only expressed as 0.2 (the difference is a charge state of 1amu / 5). High-resolution / high-accuracy mass spectrometers are able to distinguish isotopic forms of highly multi-charged ions (such as ions with charges of ±5, ±6, ±7, ±8, ±9 or higher).
[0079] Due to naturally occurring element isotopes, each molecular ion usually has multiple isotopic forms (if analyzed with a sufficiently sensitive mass spectrometer, each isotopic form may produce a separately detectable spectral peak). The m / z ratio and relative abundance of multiple isotopic forms together constitute the isotopic characteristics of the molecular ion. In certain embodiments, the m / z ratio and relative abundance of two or more molecular isotopic forms can be used to confirm the identity of the molecular ion being studied. In certain embodiments, the mass spectrum peaks from one or more isotopic forms are used for quantitative molecular ions. In some related embodiments, a single mass spectrum peak from a kind of isotopic form is used for quantitative molecular ions. In other related embodiments, multiple isotopic peaks are used for quantitative molecular ions. In these latter embodiments, multiple isotopic peaks can be subjected to any appropriate mathematical treatment. Several mathematical treatments are known in the art and include but are not limited to summing the areas under multiple peaks or averaging the responses from multiple peaks.
[0080] Typically in mass spectrometry, several detection modes can be used to detect ions. For example, selected ions can be detected, i.e., using a selective ion monitoring mode (SIM), or alternatively, scan mode detection ions can be used. When operating in scan mode, a mass spectrometer typically provides an ion scan for a user; i.e., the relative abundance of each ion with a specific mass / charge within a given range (e.g., 100 to 1000 amu). Further, when using an instrument capable of multiple mass spectrometry events, such as some ion traps or triple quadrupole instruments, mass transfer caused by (e.g., multiple reaction monitoring (MRM) or selected reaction monitoring (SRM)) collision-induced dissociation or neutral loss can be monitored.
[0081] The result of the analyte determination (i.e., mass spectrum) can be associated with the amount of the analyte in the original sample by various methods known in the art. For example, if the sampling and analysis parameters are carefully controlled, the relative abundance of a given ion can be compared with a table that converts the relative abundance into the absolute amount of the original molecule. Alternatively, an internal or external standard can be run with the sample, and a standard curve is constructed based on the ions produced by these standards. Using such a standard curve, the relative abundance of a given ion can be converted into the absolute amount of the original molecule. In certain preferred embodiments, one or more standards are used to generate a standard curve for calculating the amount of IGF-2 protein. The method of generating and using such a standard curve is well known in the art, and a person of ordinary skill can select an appropriate internal standard. For example, in a preferred embodiment, isotope-labeled or unlabeled non-human IGF-2 (e.g., recombinant mouse IGF-2) or isotope-labeled human IGF-2 can be used as a standard. A variety of other methods for correlating the amount of ions with the amount of the original molecule will be well known to a person of ordinary skill in the art.
[0082] As used herein, "isotopic labeling" produces a mass shift in the labeled molecule relative to the unlabeled molecule when analyzed by mass spectrometry techniques. Examples of suitable labels include deuterium ( 2 H), 13 C and 15 N. An isotopic label may be incorporated at one or more positions in a molecule, and one or more isotopic labels may be used on the same isotopically labeled molecule.
[0083] One or more steps of the method may be performed using automated machines. In certain embodiments, one or more purification steps are performed online, and more preferably all of the purification and mass spectrometry steps may be performed in an online manner.
[0084] In some embodiments, MS is used to detect and / or quantify IGF-2 variants in a sample as follows. The sample is subjected to liquid chromatography, preferably HPLC; a liquid solvent stream from the chromatographic column enters a heated nebulizer interface of an ESI ionization source; and the solvent / analyte mixture is converted into vapor in a heated charged conduit of the interface. By applying a large voltage to the solvent / analyte mixture, the analyte (e.g., IGF-2 variant) contained in the solvent is ionized. When the analyte leaves the charged conduit of the interface, the solvent / analyte mixture is atomized and the solvent evaporates, leaving behind analyte ions in various charge states. Quantitative data of the intensity of one or more of the ions is then collected. Quantitative data of the signal intensity of one or more ions is then collected and the quantitative data is associated with the number of IGF-2 variants in the sample.
[0085] For IGF-2 variants, ions in various charge states can be observed with m / z. In addition, at this level of precision, the observed mass of any ion may vary slightly, e.g., ±0.1, due to instrumental variation.
[0086] In some embodiments, the use of a high resolution / high accuracy mass spectrometer can allow the signal intensity of a peak from a single isotopic form of a single ion to be selected for data acquisition. Alternatively, quantitative data of the signal intensity of one or more isotopic forms of a single ion or the signal intensity across a narrow m / z range can be collected and correlated with the amount of IGF-2 variant in the sample.
[0087] In some embodiments, quantitative data of the signal intensity of one or more IGF-2 ions from at least two different charge states are collected. Then, the intensity of these ions can be used for the quantitative assessment of IGF-2 variants in the sample. For example, the IGF-2 variant can be quantified with the signal intensity from one or more ions in an 8+ charge state or a 7+ charge state. In embodiments where quantitative data of the signal intensity of two or more ions is collected, the intensity can be combined by any mathematical method known in the art (such as summing, or averaging the area under the curve) to quantitatively assess the IGF-2 variants in the sample.
[0088] When ions collide with the detector, the ions will generate electronic pulses, and the electrons are converted into digital signals. The acquired data are relayed to a computer, which plots the relationship between the collected ion counts and time. The resulting mass spectrum is similar to the chromatogram generated in the traditional HPLC-MS method. The area under the peak corresponding to a specific ion or the amplitude of such peaks can be measured and is related to the amount of the analyte of interest. In certain embodiments, the amplitude of the area under the curve or the peak is measured to determine the amount of IGF-I and / or IGF-II protein or fragment. As described above, the relative abundance of a given ion can be converted into the absolute amount of the original analyte using a calibration standard curve based on the peak of one or more ions of an internal molecular standard.
[0089] In some embodiments, IGF-1 and IGF-2 are quantified simultaneously. In these embodiments, each of IGF-1 and IGF-2 can be quantified individually by any of the methods provided above.
[0090] In certain preferred embodiments, the lower limit of quantification (LLOQ) of the IGF-2 variant is in the range of about 30.0 ng / mL to 200 ng / dL (inclusive); preferably in the range of about 30.0 ng / dL to 100 ng / mL (inclusive); preferably in the range of about 30.0 ng / mL to 50 ng / mL (inclusive); preferably in the range of about 30.0 ng / mL to 25 ng / mL (inclusive); preferably in the range of about 30.0 ng / mL to 15 ng / mL (inclusive); preferably in the range of about 30.0 ng / mL to 10 ng / mL (inclusive); preferably about 30.0 ng / mL.
[0091] In certain preferred embodiments, the limit of detection (LOD) of the IGF-2 variant is in the range of about 8.2 ng / mL to 200 ng / mL (inclusive); preferably in the range of about 8.2 ng / mL to 100 ng / mL (inclusive); preferably in the range of about 8.2 ng / mL to 50 ng / mL (inclusive); preferably in the range of about 8.2 ng / mL to 25 ng / mL (inclusive); preferably in the range of about 8.2 ng / mL to 20 ng / mL (inclusive); preferably about 8.2 ng / mL.
[0092] The following examples are used to illustrate the present invention. These examples are in no way intended to limit the scope of the present method. Specifically, the following examples demonstrate the use of specific internal standards to quantify IGF-2 proteins or fragments by mass spectrometry. The use of the indicated internal standards is not intended to be limited in any way. Any suitable chemical species readily determined by a person skilled in the art can be used as an internal standard.
[0093] Examples
[0094] Example 1: Identification of IGF-2 variants by mass spectrometry
[0095] During the analysis of IGF-1 variants, an anomalous variant was detected at VG1. When detected at IP1, its relative retention time (rRT) was -0.19 minutes, which did not match any previously identified variant. MS / MS detected the PAK sequence from the C-terminus. The anomalously high y ion mass of 214 Da heavier than the predicted ion mass could be explained by heavy modifications of the last two amino acids or heavy modifications of the C-terminus. However, no such candidate was found in the list of post-translational modifications (PTMs). Figure 1 :
[0096] Even more puzzling, the protein’s overall mass was 30.9 daltons lighter than WT IGF-1. This mystery remained unexplained until another sample with the same modification was discovered. Figure 2 :
[0097] Another sample was sequenced by MS / MS and this time produced a much better spectrum. Two additional C-terminal amino acids were identified, resulting in the sequence ATPAK. In addition, an attempt was made to sequence the N-terminus of the ETL sequence detected. All of these new findings were even more confusing: all y ions were 214 Da heavier than the predicted ions; y6 and y7 did not match the WT IGF-1 sequence; the N-terminal ion ETL was 420 Da heavier than the predicted ion; and the total protein mass was 30 Da lighter than WT IGF-1. Figure 3 :
[0098] The C-terminal sequence ATPAK was identified using BLAST search. One potential candidate is IGF-2, a structurally similar protein. Figure 4 :
[0099] The assumption is changed and the hypothesis is that this is an IGF-2 variant. The N-terminus of IGF-2 begins with the sequence AYRPSETL, which contains the ETL fragment, but has a heavier m / z due to the presence of the remaining amino acids (the IGF-1 sequence is simply GPETL). However, the C-terminus of the IGF-2 variant still has an additional 156 Da to account for (now measured against the IGF-2 sequence). This mass difference corresponds to a C-terminal arginine (R) stretch of the mature IGF-2 sequence (1-67). R68 follows the C-terminus of the mature IGF-2 polypeptide sequence and is the first amino acid of the prohormone E domain. If this possibility is taken into account, all inconsistencies resolve: all b-ions and y-ions are matched to the correct m / z ratios and the overall m / z of the protein matches the theoretical value exactly to within 0.6 ppm. Conclusion: This is an example of an IGF-2 protein with an R stretch (ATPAKSER) at the C-terminus. Figure 5 :
[0100] The m / z used to detect the IGF-2 variant was 1089.8092, detected at IP1.
[0101] In the IGF-2 prohormone, the E domain (68-156) starting with R is cleaved during protein maturation, leaving only the WT IGF-2 sequence. In the present case, R appears to be retained together with the IGF-2 sequence. As far as is known, IGF-2 (1-68) has never been observed before. It may have some relationship with the so-called "big IGF-2", which is described as an IGF-2 protein in which an incorrect cleavage produces additional amino acids from the E domain of the pro-IGF-2 sequence. Two large IGF-2 polypeptides described in the literature (1-87 and 1-104) are both biomarkers for non-islet cell tumor hypoglycemia (NICTH). Figure 6 :
[0102] Conclusion: The workflow for routine monitoring of IGF-1 variants resulted in the detection of an aberrant IGF-2 species (1-68), indicating the presence of an unexpected prohormone process of unknown clinical significance and unknown frequency.
[0103] The contents of the articles, patents, and patent applications mentioned or cited herein, and all other documents and electronically available information are hereby incorporated by reference in their entirety, to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicants reserve the right to physically incorporate into this application any and all materials and information from any such articles, patents, patent applications, or other physical and electronic documents.
[0104] The methods illustratively described herein can be appropriately practiced in the absence of any one or more elements, one or more limitations not specifically disclosed herein. Therefore, for example, the terms "include", "comprise", "contain", etc. should be understood extensively and are not limited. In addition, the terms and expressions adopted herein have been used as descriptive and non-restrictive terms, and there is no intention to use such terms and expressions to exclude any equivalents or parts thereof of the features shown and described. It should be recognized that various modifications are possible within the scope of the present invention. Therefore, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modifications and variations of the invention implemented therein disclosed herein may be adopted by those skilled in the art, and such modifications and variations are considered to be within the scope of the present invention.
[0105] The invention is described broadly and generally herein. Each of the narrower species and subgeneric groups falling within the general disclosure also forms part of the methods. This includes the general description of the methods with the proviso or negative limitation that any subject matter is removed from the genus, regardless of whether the deleted material is specifically recited herein.
[0106] Other embodiments are within the following claims.In addition, where features or aspects of the methods are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
Claims
1. A method for detecting an insulin-like growth factor-2 (IGF-2) variant in a sample, the method comprising: a. ionizing the IGF-2 variant in the sample to produce one or more ions that can be detected by mass spectrometry; b. detecting one or more of the ions by mass spectrometry, wherein the one or more ions include ions having a mass-to-charge ratio of 1089.8±0.5; and c. Using the detected one or more ions to determine the presence of the IGF-2 variant in the sample. 2 . The method of claim 1 , wherein the method detects variants having an additional arginine at position 68.
3. The method of claim 1, further comprising purifying the protein by high performance liquid chromatography (HPLC) prior to ionization. The method of claim 1 , wherein the sample comprises plasma or serum.
